[ad_1]
TORONTO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Skylight Health Group Inc. (TSXV:SLHG; OTCKKS:SLHGF) (“Skylight Health” or the “Company”), a healthcare platform that combines technology and analytics focused on transitioning patients into value-based care to drive better healthcare outcomes and experiences in the United States, announced is that its Board of Directors has authorized and the Company has declared a dividend on its Series A Cumulative Redeemable Perpetual Preferred Shares of 9.25% (“Series A Preferred Shares”) for the month of January 2023. The Series A Preferred Shares trade under the symbol “SLHGP” .
Pursuant to the terms of the Series A Preferred Stock, the Series A dividend will be paid in cash in the amount of $0.1927 per share on January 20, 2023 to stockholders of record in the Series A Preferred Stock on the December 30 dividend record date. in 2022.
The Company also wishes to update the details of the Company’s previously announced shares of debt on September 15 and 16, 2022. The Company will settle a total of $438,400 of debt by issuing a total of 626,286 common shares to creditors at an estimated price of $0.70 per common share, to satisfy the debt.
About Skylight Health Group
Skylight Health Group (TSKSV:SLHG OTCKKS:SLHGF) is a healthcare services and technology company working to positively impact patient health outcomes. The company operates a multi-state primary care network in the US consisting of physical practices that provide a range of services from primary care, subspecialty, allied health and laboratory/diagnostic testing. The company is focused on helping small and independent practices transition from traditional fee-for-service (“FFS“) value-based care model (“VBC“) through tools that include proprietary technology, data analytics and infrastructure. In the FFS model, payers (commercial and government insurers) reimburse based on an encounter-based approach. This puts the focus on the number of patients per day. In the VBC model, providers offer care that is focused on maintaining patient health and minimizing unnecessary health care costs that have not been proven to maintain patient well-being. This puts the emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced delivery costs and drive better financial performance from existing practices.
Forward-looking statements
This press release may include predictions, estimates or other information that may be considered forward-looking within the meaning of applicable securities laws. Although these forward-looking statements represent our current estimates, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date hereof. Please note that we undertake no obligation to revise or publicly announce the results of any revisions to these forward-looking statements in light of new information or future events. When used herein, words such as “look forward”, “believe”, “continue”, “build” or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated by any forward-looking statements made herein are often discussed in filings we file with Canadian securities regulators and Canadian securities administrators, available at www.sedar.com and on our website, at skylighthealthgroup.com.
For more information visit our website or contact:
Investor Relations:
Jackie Kelly
investors@skilighthealthgroup.com
416-301-2949
Neither TSKS Venture Exchange nor its regulation service provider (as that term is defined in the policies of TSKS Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
[ad_2]
Source link
